toxicity

The importance of managing hematologic toxicity associated with CAR-T therapy 2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML 2:08
Results from a Phase I trial of rapidly manufactured Prgn-3006 Ultracar-T in R/R AML
David Sallman • 11 Dec 2022
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL 3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
Overexpression of the LBTR gene to optimize T cell proliferation 1:54
Overexpression of the LBTR gene to optimize T cell proliferation
Mateusz Legut • 31 Mar 2022
Novel approaches in lymphocyte engineering 3:31
Novel approaches in lymphocyte engineering
Elvira D’Ippolito • 31 Mar 2022
Challenges to address in the CAR-T field 4:58
Challenges to address in the CAR-T field
John Rossi • 26 Aug 2021
ESGCT 2021 highlights: AAV vector capsid modification for CNS disorders 1:48
ESGCT 2021 highlights: AAV vector capsid modification for CNS disorders
Michael Hocquemiller • 15 Nov 2021
ISCT 2021 highlights: BMT, gene therapy & lymphodepletion 4:30
ISCT 2021 highlights: BMT, gene therapy & lymphodepletion
Jaap Boelens • 26 May 2021
The content of VJRegenMed is intended for healthcare professionals